focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 337.00
Bid: 333.00
Ask: 337.00
Change: -3.00 (-0.88%)
Spread: 4.00 (1.201%)
Open: 335.00
High: 337.00
Low: 329.00
Prev. Close: 340.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chi-Med to Attend Upcoming Investor Conferences

11 May 2020 07:00

RNS Number : 3486M
Hutchison China Meditech Limited
11 May 2020
 

Press Release

Chi-Med to Attend Upcoming Investor Conferences

London: Friday, May 11, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight Time (EDT).

 

The discussion will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under "Events, Circulars & Forms." Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

 

Members of the senior management team will also attend virtual one-on-one meetings at the Bank of America Health Care Conference on May 14, as well as during the following other conferences:

 

· Citi Virtual Pan-Asia Regional Investor Conference from Tuesday to Thursday, May 19 to 21, 2020;

 

· Jefferies Virtual Global Healthcare Conference from Tuesday to Thursday, June 2 to 4, 2020; and

 

· Goldman Sachs Global Healthcare Conference Webcast from Tuesday to Thursday, June 9 to 11, 2020.

 

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

 

CONTACTS

Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

 

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Chi-Med@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com

Nominated Advisor

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAMZGGKRRZGGZG
Date   Source Headline
13th May 20157:00 amRNSFruquintinib results trigger payments from Lilly
30th Apr 20157:00 amRNSTotal Voting Rights
24th Apr 201512:40 pmRNSResult of AGM
22nd Apr 201511:23 amRNSDirector/PDMR Shareholding
16th Apr 20151:19 pmRNSDirector's Shareholding
13th Apr 20158:07 amRNSDirector's Shareholding
8th Apr 20158:18 amRNSDirectors' Shareholding
1st Apr 20153:48 pmRNSDirectors Shareholding
1st Apr 20152:32 pmRNSExercise of Options
30th Mar 20157:00 amRNSTrial of fruquintinib achieves primary endpoint
23rd Mar 20157:00 amRNSNotice of AGM
18th Mar 20157:08 amRNSNotification of Major Interest in Shares
6th Mar 20157:06 amRNSPatient enrolment completion for Phase II study
26th Feb 20157:00 amRNSFinal Results
29th Jan 20157:00 amRNSDistribution Agreement for Seroquel in China
26th Jan 20157:00 amRNSNotice of Results
31st Dec 20147:00 amRNSTotal Voting Rights
29th Dec 20147:00 amRNSBlocklisting Six Monthly Return
15th Dec 20147:00 amRNSInitiation of fruquintinib Phase III study
31st Oct 20147:03 amRNSTotal Voting Rights
7th Oct 20147:00 amRNSDrug R&D Update Briefing
1st Oct 20147:00 amRNSCo-promotion agreement with Merck Serono
19th Sep 20149:13 amRNSHolding(s) in Company
21st Aug 20147:00 amRNSPatient enrolment in Phase II study completed
13th Aug 20147:00 amRNSHMPL-004 Interim Analysis
29th Jul 20147:00 amRNSInterim Results
30th Jun 20147:00 amRNSBlocklisting Interim Review
30th Jun 20147:00 amRNSTotal Voting Rights
26th Jun 20147:00 amRNSNotice of Results
25th Jun 20147:00 amRNSChi-Med Refinancing of Existing Loan Facility
18th Jun 20147:00 amRNSStart of Phase I clinical trial with HMPL-523
5th Jun 20147:00 amRNSInitiation of fruquintinib Phase II study
4th Jun 20141:52 pmRNSDirector's Shareholding
3rd Jun 20143:23 pmRNSExercise of Options
30th May 20149:10 amRNSGains rights to six prescription drug products
23rd May 20147:00 amRNSInitiation of Phase II Study in Renal Cancer
22nd May 20147:00 amRNSPhase I data to be presented at ASCO
8th May 201411:54 amRNSResult of AGM
17th Apr 20147:00 amRNSChi-Med and Sinopharm Deal Approved
4th Apr 20147:00 amRNSInitiation of Phase II study in colorectal cancer
4th Apr 20147:00 amRNSPresentations at the 2014 AACR Annual Meeting
28th Mar 20147:00 amRNS2013 Annual Report and Notice of AGM
18th Feb 20147:00 amRNSFinal Results
13th Feb 20148:14 amRNSNotification of Major Interest in Shares
16th Jan 20147:00 amRNSNotice of Results
30th Dec 20137:00 amRNSBlocklisting Six Monthly Return
18th Dec 20139:02 amRNSSinopharm distribution joint venture in China
16th Oct 201311:58 amRNSDirector/PDMR Shareholding
9th Oct 20137:00 amRNSPayment From Janssen Pharmaceuticals
9th Oct 20137:00 amRNSLilly Deal for Fruquintinib

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.